We are live on ! Find out more
HMC

Harvard Management Company Portfolio holdings

AUM $1.82B
1-Year Est. Return 26.23%
This Fund
S&P 500
This Quarter Est. Return
-4.52%
1 Year Est. Return
+26.23%
3 Year Est. Return
+156.3%
5 Year Est. Return
+133.98%
10 Year Est. Return
+221.37%
AUM
$1.07B
AUM Growth
-$641M
Cap. Flow
-$556M
Cap. Flow %
-52.17%
Top 10 Hldgs %
75.23%
Holding
55
New
15
Increased
–
Reduced
5
Closed
9

Top Buys

Rank Stock Value
1
EQRX
EQRx, Inc. Common Stock
EQRX
+$49.7M
2
GRAB icon
Grab
GRAB
+$15.3M
3
CFLT
Confluent
CFLT
+$9.4M
4
MU icon
Micron Technology
MU
+$8.02M
5
LRCX icon
Lam Research
LRCX
+$7.85M

Top Sells

Rank Stock Value
1
AAPL icon
Apple
AAPL
+$267M
2
RPRX icon
Royalty Pharma
RPRX
+$143M
3
META icon
Meta Platforms (Facebook)
META
+$113M
4
AFRM icon
Affirm
AFRM
+$76.7M
5
QQQ icon
Invesco QQQ Trust
QQQ
+$36.3M

Sector Composition

Rank Sector Weight
1 Healthcare 40.23%
2 Communication Services 28.34%
3 Consumer Discretionary 16.85%
4 Technology 9.73%
5 Financials 2.72%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TSM icon
26
TSMC
TSM
$2.16T
$7.75M 0.73%
+64,443
New +$7.55M
TNGX icon
27
Tango Therapeutics
TNGX
$4.78B
$7.75M 0.73%
708,385
– –
NVDA icon
28
NVIDIA
NVDA
$5.13T
$7.74M 0.73%
+263,150
New +$7.24M
PLRX icon
29
Pliant Therapeutics
PLRX
$65M
$7.59M 0.71%
562,379
– –
QRVO icon
30
Qorvo
QRVO
$8.38B
$7.34M 0.69%
+46,963
New +$7.47M
ADI icon
31
Analog Devices
ADI
$185B
$7.34M 0.69%
+41,739
New +$7.4M
FULC icon
32
Fulcrum Therapeutics
FULC
$290M
$7.27M 0.68%
410,714
– –
SANA icon
33
Sana Biotechnology
SANA
$946M
$7.26M 0.68%
468,749
-694,852
-60% -$13.4M
ASML icon
34
ASML
ASML
$658B
$7.19M 0.68%
+9,034
New +$7.18M
XLO icon
35
Xilio Therapeutics
XLO
$59.8M
$6.66M 0.62%
+29,719
New +$7.09M
PRDS
36
DELISTED
Pardes Biosciences, Inc. Common Stock
PRDS
$6.55M 0.61%
400,000
– –
SRZN icon
37
Surrozen
SRZN
$255M
$5.33M 0.5%
55,123
– –
PACB icon
38
Pacific Biosciences
PACB
$447M
$4.69M 0.44%
229,144
– –
GBIO
39
DELISTED
Generation Bio
GBIO
$3.61M 0.34%
51,035
– –
DBTX
40
DELISTED
Decibel Therapeutics, Inc. Common Stock
DBTX
$1.53M 0.14%
328,798
– –
DNTH icon
41
Dianthus Therapeutics
DNTH
$6.04B
$1.47M 0.14%
20,788
– –
DYN icon
42
Dyne Therapeutics
DYN
$4.85B
$1.27M 0.12%
107,252
– –
MCRB icon
43
Seres Therapeutics
MCRB
$50.8M
$1.1M 0.1%
6,592
– –
IRON icon
44
Disc Medicine
IRON
$2.99B
$728K 0.07%
8,333
– –
DADA
45
DELISTED
Dada Nexus
DADA
$531K 0.05%
+40,338
New +$778K
SRZNW icon
46
Surrozen Inc Warrant
SRZNW
$125K 0.01%
108,333
– –
AAPL icon
47
Apple
AAPL
$4.52T
– –
-1,883,445
Closed -$267M
AMPL icon
48
Amplitude
AMPL
$1.31B
– –
-540
Closed -$29K
GLD icon
49
SPDR Gold Trust
GLD
$132B
– –
-91,955
Closed -$15.1M
IJH icon
50
iShares Core S&P Mid-Cap ETF
IJH
$126B
– –
-63,415
Closed -$3.34M
1
2
3

Similar funds

DWT
Dorsey & Whitney Trust Sioux Falls, South Dakota $1.82B AUM 19.69% 1-Year Est. Return
SI
Standard Investments New York $1.83B AUM 4.12% 1-Year Est. Return
GC
Gobi Capital San Francisco, California $1.8B AUM 7.28% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
KAM
Kensington Asset Management Austin, Texas $1.84B AUM 13.95% 1-Year Est. Return
OQS
Occudo Quantitative Strategies Fort Lauderdale, Florida $1.84B AUM 22.15% 1-Year Est. Return
RP
Regal Partners Sydney, NSW, Australia $1.84B AUM 54.78% 1-Year Est. Return
BP
BBR Partners New York $1.79B AUM 16.83% 1-Year Est. Return

Harvard Management Company's Q4 2021 Portfolio in Review

As of Q4 2021, Harvard Management Company held 55 positions worth $1.07B, down 38% from $1.71B the previous quarter. Its ten largest holdings account for 75% of the portfolio.

Harvard Management Company withdrew a net $556M in Q4 2021, closing 9 positions and reducing 5 holdings. Its most notable exit was Apple, an estimated $267M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 40% of assets, up from 34% a quarter earlier, followed by Communication Services and Consumer Discretionary.

Against the trend, Harvard Management Company opened a new position in EQRx, Inc. Common Stock worth $35.9M.

  • Harvard Management Company's largest Q4 2021 buy was EQRx, Inc. Common Stock: 5,262,161 shares worth $35.9M.
  • Harvard Management Company's biggest Q4 2021 reduction was Royalty Pharma, cutting an estimated $143M.
  • Harvard Management Company fully exited Apple in Q4 2021, selling an estimated $267M.
  • Harvard Management Company's ten largest holdings make up 75% of its $1.07B portfolio in Q4 2021.
  • Harvard Management Company opened 15 new positions and closed 9 in Q4 2021.
  • Harvard Management Company's portfolio value fell 38% quarter-over-quarter to $1.07B.

Based on Harvard Management Company's 13F filing for Q4 2021, filed 11 Feb 2022.